cui1,cui2,relation,name1,name2,type1,type2,weight,predicate
C0001637,C0232341,TREATS,Adrenergic Agents,Increased vascular flow,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001640,C0020649,TREATS,Adrenergic alpha-Agonists,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001641,C0425710,TREATS,Adrenergic alpha-Antagonists,Peripheral perfusion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001644,C0349790,TREATS,Adrenergic beta-Agonists,Exacerbation of asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001644,C0743630,TREATS,Adrenergic beta-Agonists,exacerbation acute,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C0035213,TREATS,Adrenergic beta-Antagonists,Pulmonary Ventilation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C0150312,TREATS,Adrenergic beta-Antagonists,Present,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0001645,C0428977,TREATS,Adrenergic beta-Antagonists,Bradycardia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C0600061,TREATS,Adrenergic beta-Antagonists,Serum creatinine level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C1444656,TREATS,Adrenergic beta-Antagonists,Indicated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C3272283,TREATS,Adrenergic beta-Antagonists,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0001645,C3276943,TREATS,Adrenergic beta-Antagonists,"Hypertension, mild",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C3842676,TREATS,Adrenergic beta-Antagonists,Day 2,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C4050466,TREATS,Adrenergic beta-Antagonists,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C4746971,TREATS,Adrenergic beta-Antagonists,"Hemolytic anemia, mild",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001645,C4748623,TREATS,Adrenergic beta-Antagonists,Ventilatory support,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001648,C0235195,TREATS,Adrenergic Agonists,Sedated state,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0001648,C0700292,TREATS,Adrenergic Agonists,Hypoxemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001648,C0743630,TREATS,Adrenergic Agonists,exacerbation acute,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0001648,C4086268,TREATS,Adrenergic Agonists,Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002007,C0020649,TREATS,Aldosterone Antagonists,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002842,C1319928,TREATS,Androgen Antagonists,Female-to-male transsexual (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002932,C0038435,TREATS,Anesthetics,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002932,C0235195,TREATS,Anesthetics,Sedated state,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0002932,C0683521,TREATS,Anesthetics,Patient Physiological Condition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002932,C0740941,TREATS,Anesthetics,Lung Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0002932,C0750484,TREATS,Anesthetics,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0001925,TREATS,Angiotensin-Converting Enzyme Inhibitors,Albuminuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0009488,TREATS,Angiotensin-Converting Enzyme Inhibitors,Comorbidity,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0003015,C0020649,TREATS,Angiotensin-Converting Enzyme Inhibitors,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0033687,TREATS,Angiotensin-Converting Enzyme Inhibitors,Proteinuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0035648,TREATS,Angiotensin-Converting Enzyme Inhibitors,risk factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0087130,TREATS,Angiotensin-Converting Enzyme Inhibitors,Uncertainty,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0241863,TREATS,Angiotensin-Converting Enzyme Inhibitors,diabetic,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C0003015,C0332149,TREATS,Angiotensin-Converting Enzyme Inhibitors,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C0677946,TREATS,Angiotensin-Converting Enzyme Inhibitors,Stable Disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C1275743,TREATS,Angiotensin-Converting Enzyme Inhibitors,Co-morbid conditions,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C1444662,TREATS,Angiotensin-Converting Enzyme Inhibitors,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C1854494,TREATS,Angiotensin-Converting Enzyme Inhibitors,Slow progression,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C3151529,TREATS,Angiotensin-Converting Enzyme Inhibitors,Lethal,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C3272281,TREATS,Angiotensin-Converting Enzyme Inhibitors,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C3272283,TREATS,Angiotensin-Converting Enzyme Inhibitors,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003015,C3714738,TREATS,Angiotensin-Converting Enzyme Inhibitors,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C3869937,TREATS,Angiotensin-Converting Enzyme Inhibitors,T1d,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C4013784,TREATS,Angiotensin-Converting Enzyme Inhibitors,"Hypertension, severe",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C4050466,TREATS,Angiotensin-Converting Enzyme Inhibitors,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C4055506,TREATS,Angiotensin-Converting Enzyme Inhibitors,Accumulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003015,C4699158,TREATS,Angiotensin-Converting Enzyme Inhibitors,Increased risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003138,C4289767,TREATS,Antacids,Colonization,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C0150312,TREATS,Anthelmintics,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003158,C0191554,TREATS,Anthelmintics,Horn has been removed,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C0221198,TREATS,Anthelmintics,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C0237677,TREATS,Anthelmintics,insensitivity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C0595939,TREATS,Anthelmintics,Stillbirth,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C0679252,TREATS,Anthelmintics,cure of disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003158,C4533736,TREATS,Anthelmintics,Low pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003191,C0332149,TREATS,Antirheumatic Agents,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003191,C0683525,TREATS,Antirheumatic Agents,treatment options,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003191,C2220266,TREATS,Antirheumatic Agents,exposure history,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003195,C0518609,TREATS,Anti-Arrhythmia Agents,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003204,C0439663,TREATS,Anti-Infective Agents,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003204,C1299586,TREATS,Anti-Infective Agents,Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003205,C0007294,TREATS,"Anti-Infective Agents, Local",Genetic Carriers,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0009940,TREATS,Anti-Inflammatory Agents,Convalescence,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0026858,TREATS,Anti-Inflammatory Agents,Musculoskeletal Pain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0033687,TREATS,Anti-Inflammatory Agents,Proteinuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0033774,TREATS,Anti-Inflammatory Agents,Pruritus,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003209,C0150312,TREATS,Anti-Inflammatory Agents,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003209,C0151602,TREATS,Anti-Inflammatory Agents,Facial swelling (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0231224,TREATS,Anti-Inflammatory Agents,Crisis,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0234708,TREATS,Anti-Inflammatory Agents,Raised intraocular pressure (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0240320,TREATS,Anti-Inflammatory Agents,medication use,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0332149,TREATS,Anti-Inflammatory Agents,Possible,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003209,C0439662,TREATS,Anti-Inflammatory Agents,Immune,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0442797,TREATS,Anti-Inflammatory Agents,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0522568,TREATS,Anti-Inflammatory Agents,Moderate inflammation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0522569,TREATS,Anti-Inflammatory Agents,Severe inflammation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003209,C0576962,TREATS,Anti-Inflammatory Agents,Tooth problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0743626,TREATS,Anti-Inflammatory Agents,etiology unknown,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C0748864,TREATS,Anti-Inflammatory Agents,small size,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C1290992,TREATS,Anti-Inflammatory Agents,Smooth muscle spasm,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C1301624,TREATS,Anti-Inflammatory Agents,Medical contraindication,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C1333602,TREATS,Anti-Inflammatory Agents,Favorable Clinical Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C1545588,TREATS,Anti-Inflammatory Agents,Protection,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0003209,C1832073,TREATS,Anti-Inflammatory Agents,Handling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C1836348,TREATS,Anti-Inflammatory Agents,Severe disorder,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003209,C1836407,TREATS,Anti-Inflammatory Agents,Early death,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C3890735,TREATS,Anti-Inflammatory Agents,Complete Response with Incomplete Platelet Recovery,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003209,C4050466,TREATS,Anti-Inflammatory Agents,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003209,C4086268,TREATS,Anti-Inflammatory Agents,Exacerbation,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0003209,C4699158,TREATS,Anti-Inflammatory Agents,Increased risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0009488,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0026858,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Musculoskeletal Pain,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003211,C0150312,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Present,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003211,C0158915,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Exceptionally large baby (disorder),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0277786,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Chief complaint (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0278138,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Mild pain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0278140,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Severe pain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0332149,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0425946,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Short menstrual periods,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0436345,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Symptom severe,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0003211,C0439663,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C0522567,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Mild inflammation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C1281905,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",At risk of disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C1299586,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C1317600,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",patient symptoms,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C2220266,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",exposure history,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C3272283,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003211,C3841427,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Medical reasons,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C3872830,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Inflammatory lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C4554631,TREATS,"Anti-Inflammatory Agents, Non-Steroidal","Nasal Congestion, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003211,C4698719,TREATS,"Anti-Inflammatory Agents, Non-Steroidal",Confirmed case,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0009488,TREATS,Anticoagulants,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0150312,TREATS,Anticoagulants,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003280,C0262926,TREATS,Anticoagulants,Medical History,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0439663,TREATS,Anticoagulants,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0442797,TREATS,Anticoagulants,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0683314,TREATS,Anticoagulants,personal health,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0701159,TREATS,Anticoagulants,Patient in hospital,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C0742969,TREATS,Anticoagulants,D-dimer above reference range,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0003280,C1301624,TREATS,Anticoagulants,Medical contraindication,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C1444662,TREATS,Anticoagulants,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C1836348,TREATS,Anticoagulants,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C3272283,TREATS,Anticoagulants,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C4025286,TREATS,Anticoagulants,Recurrent thromboembolism,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C4050466,TREATS,Anticoagulants,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003280,C4321237,TREATS,Anticoagulants,High Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003280,C4697669,TREATS,Anticoagulants,Reconstituted,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003286,C3843787,TREATS,Anticonvulsants,10 - 12,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003289,C0332149,TREATS,Antidepressive Agents,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003289,C0424594,TREATS,Antidepressive Agents,Frailty,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003289,C0682132,TREATS,Antidepressive Agents,regional difference,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003289,C3890735,TREATS,Antidepressive Agents,Complete Response with Incomplete Platelet Recovery,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003289,C4699158,TREATS,Antidepressive Agents,Increased risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003290,C0043094,TREATS,Tricyclic Antidepressive Agents,Weight Gain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003292,C0150312,TREATS,Antidiarrheals,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003295,C0239157,TREATS,Antidote,cyanide exposure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003295,C0518609,TREATS,Antidote,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003295,C0728899,TREATS,Antidote,Intoxication,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003297,C0019521,TREATS,Antiemetics,Hiccough,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003297,C0392209,TREATS,Antiemetics,Nutritional status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003297,C3714738,TREATS,Antiemetics,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003299,C0043094,TREATS,Antiepileptic Agents,Weight Gain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003299,C0521654,TREATS,Antiepileptic Agents,Neurologic Deficits,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003299,C1299590,TREATS,Antiepileptic Agents,Seizure free,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003304,C0150312,TREATS,Antifibrinolytic Agents,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003304,C0742969,TREATS,Antifibrinolytic Agents,D-dimer above reference range,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003308,C0205160,TREATS,Antifungal Agents,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003308,C0683525,TREATS,Antifungal Agents,treatment options,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003308,C0728731,TREATS,Antifungal Agents,Prematurity of fetus,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003308,C3272283,TREATS,Antifungal Agents,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003308,C4050466,TREATS,Antifungal Agents,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0009488,TREATS,Antihypertensive Agents,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0033687,TREATS,Antihypertensive Agents,Proteinuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0232202,TREATS,Antihypertensive Agents,Normal sinus rhythm,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0241863,TREATS,Antihypertensive Agents,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0424589,TREATS,Antihypertensive Agents,Vitality,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0428886,TREATS,Antihypertensive Agents,Mean blood pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0745114,TREATS,Antihypertensive Agents,hypertension chronic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C0745130,TREATS,Antihypertensive Agents,Resistant hypertensive disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003364,C4013784,TREATS,Antihypertensive Agents,"Hypertension, severe",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C0038002,TREATS,Antimalarials,Splenomegaly,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C0085639,TREATS,Antimalarials,Falls,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C0150312,TREATS,Antimalarials,Present,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003374,C0205160,TREATS,Antimalarials,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C0439663,TREATS,Antimalarials,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C1519333,TREATS,Antimalarials,Sinusoidal Infiltration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C1836348,TREATS,Antimalarials,Severe disorder,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003374,C1856381,TREATS,Antimalarials,Glucose-6-phosphate deficiency,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C3272283,TREATS,Antimalarials,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C3845888,TREATS,Antimalarials,Known allergy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C4050466,TREATS,Antimalarials,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C4055223,TREATS,Antimalarials,Clinical Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C4086268,TREATS,Antimalarials,Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C4313322,TREATS,Antimalarials,Alveolar damage,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003374,C4699705,TREATS,Antimalarials,Too long,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003376,C4050466,TREATS,Antimetabolites,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003379,C1334779,TREATS,Antimitotic Agents,Mitotic Activity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003379,C2826603,TREATS,Antimitotic Agents,Mucin Depletion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003379,C4321351,TREATS,Antimitotic Agents,Low Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003385,C0743630,TREATS,Muscarinic Antagonists,exacerbation acute,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C0086565,TREATS,Antioxidants,Liver Dysfunction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C0150312,TREATS,Antioxidants,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003402,C0231299,TREATS,Antioxidants,Decreased stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C0241863,TREATS,Antioxidants,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C0278252,TREATS,Antioxidants,Prognosis bad,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C0333361,TREATS,Antioxidants,Acute inflammation,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003402,C0349790,TREATS,Antioxidants,Exacerbation of asthma,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003402,C0683525,TREATS,Antioxidants,treatment options,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C1545588,TREATS,Antioxidants,Protection,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003402,C2748212,TREATS,Antioxidants,Viral titer Reduction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C3872830,TREATS,Antioxidants,Inflammatory lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C4021734,TREATS,Antioxidants,Abnormality of mitochondrial metabolism,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003402,C4540229,TREATS,Antioxidants,Mitochondrial oxidative stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0231221,TREATS,Antipyretics,Asymptomatic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0231262,TREATS,Antipyretics,Temperature normal,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0232973,TREATS,Antipyretics,Not pregnant (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0277799,TREATS,Antipyretics,Intermittent fever (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0439663,TREATS,Antipyretics,Infected,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003419,C0456240,TREATS,Antipyretics,Core body temperature,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0577785,TREATS,Antipyretics,Cardiac finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0677874,TREATS,Antipyretics,In complete remission,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0750484,TREATS,Antipyretics,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C0750558,TREATS,Antipyretics,Unlikely,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C1275743,TREATS,Antipyretics,Co-morbid conditions,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003419,C5203671,TREATS,Antipyretics,Suspected COVID-19,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003448,C0150312,TREATS,Antitubercular Agents,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003448,C0205160,TREATS,Antitubercular Agents,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003448,C0439663,TREATS,Antitubercular Agents,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003448,C0750484,TREATS,Antitubercular Agents,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0033213,TREATS,Antiviral Agents,Problem,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C0035648,TREATS,Antiviral Agents,risk factors,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C0003451,C0085393,TREATS,Antiviral Agents,Immunocompromised Host,phsu,fndg,11,TREATS_PHSUtrtsFNDG
C0003451,C0150312,TREATS,Antiviral Agents,Present,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C0003451,C0205160,TREATS,Antiviral Agents,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0231224,TREATS,Antiviral Agents,Crisis,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C0241863,TREATS,Antiviral Agents,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0332149,TREATS,Antiviral Agents,Possible,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C0003451,C0332575,TREATS,Antiviral Agents,Redness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0418624,TREATS,Antiviral Agents,Nonadministration of necessary drug or medicine,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0439662,TREATS,Antiviral Agents,Immune,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C0439663,TREATS,Antiviral Agents,Infected,phsu,fndg,27,TREATS_PHSUtrtsFNDG
C0003451,C0442797,TREATS,Antiviral Agents,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0475806,TREATS,Antiviral Agents,1/3 meter (distance vision finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0518609,TREATS,Antiviral Agents,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0581126,TREATS,Antiviral Agents,Severe asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0677946,TREATS,Antiviral Agents,Stable Disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0679250,TREATS,Antiviral Agents,Disease Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0683320,TREATS,Antiviral Agents,unwellness,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C0746961,TREATS,Antiviral Agents,Oxygen saturation below reference range,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C0750484,TREATS,Antiviral Agents,Confirmation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C1148363,TREATS,Antiviral Agents,Hepatitis C virus genotype (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1273390,TREATS,Antiviral Agents,curative treatment,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1299586,TREATS,Antiviral Agents,Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1320226,TREATS,Antiviral Agents,Incubation period,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1545588,TREATS,Antiviral Agents,Protection,phsu,fndg,7,TREATS_PHSUtrtsFNDG
C0003451,C1832073,TREATS,Antiviral Agents,Handling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1836348,TREATS,Antiviral Agents,Severe disorder,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C0003451,C1844666,TREATS,Antiviral Agents,Immune dysregulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C1859430,TREATS,Antiviral Agents,Life-threatening infections,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C3272283,TREATS,Antiviral Agents,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0003451,C3280118,TREATS,Antiviral Agents,Mild disorder,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C3540840,TREATS,Antiviral Agents,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C3811922,TREATS,Antiviral Agents,Liver transplant recipient,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C3842676,TREATS,Antiviral Agents,Day 2,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C3846017,TREATS,Antiviral Agents,Life threatening illness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C4050466,TREATS,Antiviral Agents,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C0003451,C4086268,TREATS,Antiviral Agents,Exacerbation,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C0003451,C4554665,TREATS,Antiviral Agents,"Cytomegalovirus Infection Reactivation, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C4699564,TREATS,Antiviral Agents,Significant activity,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0003451,C4764169,TREATS,Antiviral Agents,Increased Granules,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0003451,C5204818,TREATS,Antiviral Agents,Global Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0004110,C0392209,TREATS,Astringents,Nutritional status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0005148,C0742906,TREATS,beta-1 Interferon,Elevated C-reactive protein,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C0021294,TREATS,Bronchodilator Agents,"Infant, Premature",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C0035648,TREATS,Bronchodilator Agents,risk factors,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0006280,C0039231,TREATS,Bronchodilator Agents,Tachycardia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C0277854,TREATS,Bronchodilator Agents,dyspneic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C0442797,TREATS,Bronchodilator Agents,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C0743630,TREATS,Bronchodilator Agents,exacerbation acute,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0006280,C1275743,TREATS,Bronchodilator Agents,Co-morbid conditions,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C1704258,TREATS,Bronchodilator Agents,Abnormality,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C2945640,TREATS,Bronchodilator Agents,compromise,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C3280118,TREATS,Bronchodilator Agents,Mild disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006280,C3476546,TREATS,Bronchodilator Agents,Symptoms score,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0006280,C4086268,TREATS,Bronchodilator Agents,Exacerbation,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0006657,C0150312,TREATS,calcifediol,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006657,C0232970,TREATS,calcifediol,Postmenopausal state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006657,C0686750,TREATS,calcifediol,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006684,C0039231,TREATS,Calcium Channel Blockers,Tachycardia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006684,C0150312,TREATS,Calcium Channel Blockers,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006684,C0518609,TREATS,Calcium Channel Blockers,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0006881,C0232805,TREATS,canrenoate potassium,Normal renal function,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0007036,C0578862,TREATS,Carbonic Anhydrase Inhibitors,Intraocular pressure finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0007220,C0184511,TREATS,Cardiovascular Agents,Improved,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0007220,C1545588,TREATS,Cardiovascular Agents,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0008362,C0235266,TREATS,Choleretics,Eye irritation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0009905,C0392209,TREATS,"Contraceptives, Oral",Nutritional status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0009905,C0439663,TREATS,"Contraceptives, Oral",Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0011947,C0150312,TREATS,Dialysis Solutions,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012191,C0221198,TREATS,diethylcarbamazine,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012191,C4054987,TREATS,diethylcarbamazine,Favorable Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0020649,TREATS,Diuretics,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0021294,TREATS,Diuretics,"Infant, Premature",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0151878,TREATS,Diuretics,Prolonged QT interval,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0235266,TREATS,Diuretics,Eye irritation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0259752,TREATS,Diuretics,Hyperosmolarity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C0871269,TREATS,Diuretics,Rhythm,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012798,C1998827,TREATS,Diuretics,Respiratory Status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0012800,C0151740,TREATS,"Diuretics, Osmotic",Intracranial Hypertension,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0013036,C0231170,TREATS,Dopaminergic Agents,Disability,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013162,C0009488,TREATS,Drug Combinations,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013162,C0150312,TREATS,Drug Combinations,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013162,C0436343,TREATS,Drug Combinations,Symptom mild,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013162,C0439663,TREATS,Drug Combinations,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013162,C1318963,TREATS,Drug Combinations,Readiness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013230,C0439662,TREATS,Investigational New Drugs,Immune,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013230,C4050466,TREATS,Investigational New Drugs,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0017187,TREATS,"Drugs, Non-Prescription",Gastrointestinal problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0032972,TREATS,"Drugs, Non-Prescription",Pregnancy Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0033213,TREATS,"Drugs, Non-Prescription",Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0151849,TREATS,"Drugs, Non-Prescription",Alkaline phosphatase raised,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0746467,TREATS,"Drugs, Non-Prescription",Current Medication,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013231,C0814098,TREATS,"Drugs, Non-Prescription",health-related beliefs,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0013232,C0424601,TREATS,"Drugs, Orphan",General development,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0015314,C0239134,TREATS,Expectorants,Productive Cough,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0015314,C1659989,TREATS,Expectorants,Respiratory problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C0332149,TREATS,Fibrinolytic Agents,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C1299448,TREATS,Fibrinolytic Agents,Patient ventilated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C1998297,TREATS,Fibrinolytic Agents,Recent myocardial infarction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C2959885,TREATS,Fibrinolytic Agents,Microthrombus,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C3272281,TREATS,Fibrinolytic Agents,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0016018,C3277906,TREATS,Fibrinolytic Agents,Cardiac dysfunction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0017302,C0151740,TREATS,General anesthetic drugs,Intracranial Hypertension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0017302,C0235484,TREATS,General anesthetic drugs,cerebral hyperaemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0018100,C0332149,TREATS,Gout Suppressants,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0019120,C1821770,TREATS,Hemostatic Agents,Post-surgical bleeding,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0019593,C0442797,TREATS,Histamine H2 Antagonists,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0019593,C0679250,TREATS,Histamine H2 Antagonists,Disease Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0019593,C4289767,TREATS,Histamine H2 Antagonists,Colonization,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0020592,C0278140,TREATS,Hypnotics and Sedatives,Severe pain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0020616,C0241863,TREATS,Hypoglycemic Agents,diabetic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0022022,C0150312,TREATS,Ionophores,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0022022,C4288131,TREATS,Ionophores,Three or Four Days,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0022260,C0151613,TREATS,Isotonic Solutions,Electrolytes abnormal,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0022260,C4035627,TREATS,Isotonic Solutions,2 times,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0024911,C0038999,TREATS,Materia Medica,Swelling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0024911,C0184512,TREATS,Materia Medica,Stabilized (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0024911,C0522224,TREATS,Materia Medica,Paralysed,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0026249,C0574776,TREATS,Mitogens,Wound healed (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0026249,C1963076,TREATS,Mitogens,"Platelets, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027409,C3714738,TREATS,Narcotic Analgesics,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027410,C1820738,TREATS,Narcotic Antagonists,Feeding intolerance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027865,C0425466,TREATS,Neuromuscular Agents,Respiratory effort,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027866,C0150312,TREATS,Neuromuscular Blocking Agents,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0027866,C0412771,TREATS,Neuromuscular Blocking Agents,Spontaneous respiration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027866,C2316757,TREATS,Neuromuscular Blocking Agents,Increased creatine kinase level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0027866,C3472249,TREATS,Neuromuscular Blocking Agents,Patient ventilator dyssynchrony,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0030511,C0235229,TREATS,Parasympatholytics,Ciliary Body Spasm,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0030511,C3540840,TREATS,Parasympatholytics,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0031638,C0349790,TREATS,Phosphodiesterase Inhibitors,Exacerbation of asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0032333,C0221198,TREATS,podophyllin,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C0150312,TREATS,Protease Inhibitors,Present,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C0033607,C0332149,TREATS,Protease Inhibitors,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C0439663,TREATS,Protease Inhibitors,Infected,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0033607,C0750484,TREATS,Protease Inhibitors,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C1148363,TREATS,Protease Inhibitors,Hepatitis C virus genotype (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C1299586,TREATS,Protease Inhibitors,Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C1545588,TREATS,Protease Inhibitors,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C2004062,TREATS,Protease Inhibitors,History of previous events,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C4050171,TREATS,Protease Inhibitors,Sustained Virologic Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033607,C4055506,TREATS,Protease Inhibitors,Accumulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033613,C1545588,TREATS,Protective Agents,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033671,C0424099,TREATS,Protein Synthesis Inhibitors,Reduced concentration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C0231303,TREATS,Psychotropic Drugs,Distress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C0424575,TREATS,Psychotropic Drugs,General health,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C0728834,TREATS,Psychotropic Drugs,Place in family order: youngest sibling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C1970394,TREATS,Psychotropic Drugs,Bleeding episodes,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C3272283,TREATS,Psychotropic Drugs,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0033978,C4745084,TREATS,Psychotropic Drugs,Medical Condition,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0036088,C0043352,TREATS,Artificial saliva,Xerostomia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0036557,C0221198,TREATS,Sedatives,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0036557,C0235195,TREATS,Sedatives,Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0036557,C1457868,TREATS,Sedatives,Worse,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0036557,C1836348,TREATS,Sedatives,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0036557,C4698386,TREATS,Sedatives,Intubated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040615,C0043094,TREATS,Antipsychotic Agents,Weight Gain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040615,C0235195,TREATS,Antipsychotic Agents,Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040615,C0424000,TREATS,Antipsychotic Agents,Feeling suicidal (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040615,C0562359,TREATS,Antipsychotic Agents,Institutionalized,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C0085393,TREATS,Anti-Anxiety Agents,Immunocompromised Host,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0040616,C0184511,TREATS,Anti-Anxiety Agents,Improved,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C0241863,TREATS,Anti-Anxiety Agents,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C0518695,TREATS,Anti-Anxiety Agents,associated anxiety,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C1148363,TREATS,Anti-Anxiety Agents,Hepatitis C virus genotype (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C3272283,TREATS,Anti-Anxiety Agents,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C4321237,TREATS,Anti-Anxiety Agents,High Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0040616,C4699619,TREATS,Anti-Anxiety Agents,>40 years,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C0035648,TREATS,Trimethoprim-Sulfamethoxazole Combination,risk factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C0205160,TREATS,Trimethoprim-Sulfamethoxazole Combination,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C0311395,TREATS,Trimethoprim-Sulfamethoxazole Combination,Lameness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C0439663,TREATS,Trimethoprim-Sulfamethoxazole Combination,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C0853142,TREATS,Trimethoprim-Sulfamethoxazole Combination,CD4 Lymphocytes Decreased,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C1557112,TREATS,Trimethoprim-Sulfamethoxazole Combination,"Grade 4 Opportunistic Infection, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C1859117,TREATS,Trimethoprim-Sulfamethoxazole Combination,Recurrent pulmonary infections,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C3280118,TREATS,Trimethoprim-Sulfamethoxazole Combination,Mild disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C3714738,TREATS,Trimethoprim-Sulfamethoxazole Combination,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C3845888,TREATS,Trimethoprim-Sulfamethoxazole Combination,Known allergy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C4699572,TREATS,Trimethoprim-Sulfamethoxazole Combination,High probability,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0041044,C4699604,TREATS,Trimethoprim-Sulfamethoxazole Combination,<12 months,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0042397,C0020649,TREATS,Vasoconstrictor Agents,Hypotension,phsu,fndg,17,TREATS_PHSUtrtsFNDG
C0042397,C0020672,TREATS,Vasoconstrictor Agents,"Hypothermia, natural",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C0683525,TREATS,Vasoconstrictor Agents,treatment options,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C0742906,TREATS,Vasoconstrictor Agents,Elevated C-reactive protein,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C1299448,TREATS,Vasoconstrictor Agents,Patient ventilated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C1444662,TREATS,Vasoconstrictor Agents,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C2585422,TREATS,Vasoconstrictor Agents,Hyperdynamic circulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C2678378,TREATS,Vasoconstrictor Agents,"Hypotension, severe",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C3160731,TREATS,Vasoconstrictor Agents,Pulmonary function (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C4296962,TREATS,Vasoconstrictor Agents,Normal function,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042397,C5231182,TREATS,Vasoconstrictor Agents,Normal lung,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042398,C0429208,TREATS,Nasal Decongestants,Nasal resistance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042398,C4554631,TREATS,Nasal Decongestants,"Nasal Congestion, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0042402,C4554418,TREATS,Vasodilator Agents,Parallel,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0048045,C0150312,TREATS,4-aminomethylbenzoic acid,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0049669,C0150312,TREATS,6-methyluracil,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0051692,C3540840,TREATS,amitraz,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0052141,C0686750,TREATS,AP 10,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0053249,C0150312,TREATS,benzotriazol-1-yloxy-tris(dimethylamino)phosphonium,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0054066,C0239134,TREATS,Amoxicillin / Clavulanate,Productive Cough,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0054066,C0743630,TREATS,Amoxicillin / Clavulanate,exacerbation acute,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0054066,C3272281,TREATS,Amoxicillin / Clavulanate,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0054066,C3540840,TREATS,Amoxicillin / Clavulanate,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0054066,C4050466,TREATS,Amoxicillin / Clavulanate,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0054066,C4086268,TREATS,Amoxicillin / Clavulanate,Exacerbation,phsu,fndg,15,TREATS_PHSUtrtsFNDG
C0054066,C4740691,TREATS,Amoxicillin / Clavulanate,Moderate disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0056562,C0546884,TREATS,crystalloid solutions,Hypovolemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0065656,C0679250,TREATS,manidipine,Disease Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0070276,C0150312,TREATS,pentaerythritol,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0074176,C0086565,TREATS,schizandrin C,Liver Dysfunction,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0074176,C1545588,TREATS,schizandrin C,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0074690,C0221198,TREATS,Smectite,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0077073,C0235195,TREATS,triclofos,Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0078516,C0038187,TREATS,World Health Organization oral rehydration solution,Starvation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0078815,C0150312,TREATS,zirconium oxychloride,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0079044,C0234422,TREATS,Bronchoconstrictor Agents,Awake,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0079044,C1720436,TREATS,Bronchoconstrictor Agents,Under anesthesia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0081389,C0221198,TREATS,9-((2-phosphonylmethoxy)ethyl)guanine,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0085387,C0158915,TREATS,Cyclooxygenase Inhibitors,Exceptionally large baby (disorder),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0085387,C3540840,TREATS,Cyclooxygenase Inhibitors,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0085826,C0857460,TREATS,Antiplatelet Agents,Increased number of platelets,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0086440,C0333574,TREATS,Hypolipidemic Agents,Fatty deposition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0086466,C1317600,TREATS,Injectables,patient symptoms,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0102923,C0150312,TREATS,ametantrone,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0109081,C3834249,TREATS,Ceredase,Unlimited,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0111938,C0332575,TREATS,D 52,Redness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0114771,C0232201,TREATS,dofetilide,Sinus rhythm,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0114873,C0745114,TREATS,doxazosin,hypertension chronic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0119394,C0221198,TREATS,gluceptate,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0120742,C0332155,TREATS,Hanks Balanced Salt Solution,Did not receive therapy or drug for,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0120742,C1963076,TREATS,Hanks Balanced Salt Solution,"Platelets, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0128170,C1273489,TREATS,Methylatropine nitrate,Asthma night-time symptoms,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0139815,C0332575,TREATS,R-52,Redness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0162713,C0150312,TREATS,Photosensitizing Agents,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0162713,C0221198,TREATS,Photosensitizing Agents,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0162713,C1881693,TREATS,Photosensitizing Agents,Medical Device Incompatibility Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0162714,C0439663,TREATS,HIV Protease Inhibitors,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0162714,C0701159,TREATS,HIV Protease Inhibitors,Patient in hospital,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0178601,C0547030,TREATS,Dopamine Agonists,Visual disturbance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0205946,C1836348,TREATS,Antischistosomal Agents,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0212874,C1836348,TREATS,Lorenzo's oil,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242708,C0150312,TREATS,"Antirheumatic Drugs, Disease-Modifying",Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242708,C0151632,TREATS,"Antirheumatic Drugs, Disease-Modifying",Erythrocyte sedimentation rate raised,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242708,C0439662,TREATS,"Antirheumatic Drugs, Disease-Modifying",Immune,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242708,C3272281,TREATS,"Antirheumatic Drugs, Disease-Modifying",American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242708,C4699604,TREATS,"Antirheumatic Drugs, Disease-Modifying",<12 months,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242896,C4086268,TREATS,Anticholinergic Agents,Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242896,C4693174,TREATS,Anticholinergic Agents,Hyperreactivity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242904,C0235195,TREATS,"Anesthetics, Intravenous",Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242904,C0581126,TREATS,"Anesthetics, Intravenous",Severe asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242937,C0278138,TREATS,"Analgesics, Non-Narcotic",Mild pain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0242974,C0235195,TREATS,GABA Agonists,Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0243042,C0439663,TREATS,Inflammation Mediators,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0243042,C0743630,TREATS,Inflammation Mediators,exacerbation acute,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0243042,C4086268,TREATS,Inflammation Mediators,Exacerbation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0243042,C4747995,TREATS,Inflammation Mediators,Nasal secretions,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0259849,C4050171,TREATS,Synthetic Drugs,Sustained Virologic Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282090,C0205160,TREATS,Laxatives,Negative,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282090,C1514463,TREATS,Laxatives,Prior Therapy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282374,C0337664,TREATS,Decongestants,Smoker,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282374,C4554418,TREATS,Decongestants,Parallel,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282374,C4554631,TREATS,Decongestants,"Nasal Congestion, CTCAE",phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0282519,C1836348,TREATS,Reverse Transcriptase Inhibitors,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282568,C0231170,TREATS,"Drugs, Essential",Disability,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282568,C0231224,TREATS,"Drugs, Essential",Crisis,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282568,C0231303,TREATS,"Drugs, Essential",Distress,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0282568,C0235195,TREATS,"Drugs, Essential",Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0282568,C0443343,TREATS,"Drugs, Essential",Unstable status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302232,C1659989,TREATS,Demulcent,Respiratory problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302837,C0436345,TREATS,Vitamin supplementation,Symptom severe,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302837,C0439662,TREATS,Vitamin supplementation,Immune,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302837,C0439663,TREATS,Vitamin supplementation,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302837,C0442797,TREATS,Vitamin supplementation,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0302837,C1299448,TREATS,Vitamin supplementation,Patient ventilated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304229,C0683320,TREATS,Experimental drug,unwellness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304509,C0150312,TREATS,Inotropic agent,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C0032972,TREATS,Topical form corticosteroids,Pregnancy Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C0033774,TREATS,Topical form corticosteroids,Pruritus,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C0150312,TREATS,Topical form corticosteroids,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C0221198,TREATS,Topical form corticosteroids,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C0239573,TREATS,Topical form corticosteroids,"Fever, high-grade",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C3540840,TREATS,Topical form corticosteroids,Sign or Symptom,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0304604,C4554631,TREATS,Topical form corticosteroids,"Nasal Congestion, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0309989,C0392349,TREATS,quantum,information seeking,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0309989,C3846005,TREATS,quantum,Room air,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0310255,C0221198,TREATS,survive,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0310255,C3842672,TREATS,survive,Day 7,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0350056,C0150312,TREATS,adsorbents,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0354100,C0020461,TREATS,Loop Diuretics,Hyperkalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0354100,C4281574,TREATS,Loop Diuretics,Much,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358430,C0235195,TREATS,Muscle relaxants,Sedated state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358430,C0412771,TREATS,Muscle relaxants,Spontaneous respiration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358516,C3840880,TREATS,Medical gases,Traffic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C0150312,TREATS,Proton Pump Inhibitors,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C0151878,TREATS,Proton Pump Inhibitors,Prolonged QT interval,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C0425710,TREATS,Proton Pump Inhibitors,Peripheral perfusion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C0679250,TREATS,Proton Pump Inhibitors,Disease Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C3272283,TREATS,Proton Pump Inhibitors,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C4698386,TREATS,Proton Pump Inhibitors,Intubated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C4699158,TREATS,Proton Pump Inhibitors,Increased risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0358591,C4699604,TREATS,Proton Pump Inhibitors,<12 months,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0359086,C0518609,TREATS,oral hypoglycemic,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360105,C0038661,TREATS,Selective Serotonin Reuptake Inhibitors,Suicide,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360105,C0436345,TREATS,Selective Serotonin Reuptake Inhibitors,Symptom severe,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360105,C0683521,TREATS,Selective Serotonin Reuptake Inhibitors,Patient Physiological Condition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360105,C1760428,TREATS,Selective Serotonin Reuptake Inhibitors,Suicidal behavior,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360105,C4684773,TREATS,Selective Serotonin Reuptake Inhibitors,Serious Risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0360428,C0150312,TREATS,Cetrimide / Chlorhexidine,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0376447,C0392209,TREATS,Appetite Stimulants,Nutritional status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0376565,C0150312,TREATS,Anti-HIV Agents,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0376565,C0184511,TREATS,Anti-HIV Agents,Improved,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0376565,C0439663,TREATS,Anti-HIV Agents,Infected,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0443121,C0150312,TREATS,Cryoprecipitate,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0443121,C4700167,TREATS,Cryoprecipitate,severe hemorrhage,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0443121,C5141930,TREATS,Cryoprecipitate,Casualties,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0456388,C0020672,TREATS,Blood product,"Hypothermia, natural",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0456388,C0150312,TREATS,Blood product,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0456388,C0425152,TREATS,Blood product,Engaged to be married,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0456388,C0442797,TREATS,Blood product,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0521942,C0009488,TREATS,Angiotensin II receptor antagonist,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0521942,C0241863,TREATS,Angiotensin II receptor antagonist,diabetic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0521942,C1854494,TREATS,Angiotensin II receptor antagonist,Slow progression,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0521942,C4050466,TREATS,Angiotensin II receptor antagonist,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0543495,C1260922,TREATS,albuterol sulfate,Abnormal breathing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0544357,C0150312,TREATS,human plasma,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0544357,C0701159,TREATS,human plasma,Patient in hospital,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0544357,C4050466,TREATS,human plasma,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0556089,C0686750,TREATS,Choline supplementation,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0556112,C0683525,TREATS,Mineral supplements,treatment options,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0556113,C0150312,TREATS,trace element supplement,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0591430,C1845611,TREATS,e45,Low absolute lymphocyte count,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0597104,C0033213,TREATS,nucleoside inhibitor,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0597639,C4699164,TREATS,vasoactive agent,Poor function,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0597668,C0150312,TREATS,vitamin antagonist,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0009488,TREATS,Anti-Retroviral Agents,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0033213,TREATS,Anti-Retroviral Agents,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0237849,TREATS,Anti-Retroviral Agents,Peeling of skin,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0277787,TREATS,Anti-Retroviral Agents,Social stigmata,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0332149,TREATS,Anti-Retroviral Agents,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0439663,TREATS,Anti-Retroviral Agents,Infected,phsu,fndg,7,TREATS_PHSUtrtsFNDG
C0599685,C0458074,TREATS,Anti-Retroviral Agents,Human immunodeficiency virus (HIV) status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0522055,TREATS,Anti-Retroviral Agents,Electrocardiogram abnormal,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C0679254,TREATS,Anti-Retroviral Agents,disease recurrence,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C1411275,TREATS,Anti-Retroviral Agents,Sick person,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C1518681,TREATS,Anti-Retroviral Agents,Outcome of Therapy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C1836348,TREATS,Anti-Retroviral Agents,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C3845714,TREATS,Anti-Retroviral Agents,Several days,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599685,C4321351,TREATS,Anti-Retroviral Agents,Low Level,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0599685,C4699618,TREATS,Anti-Retroviral Agents,>65 years,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0599686,C3272283,TREATS,Nucleoside Analog Antiviral [EPC],American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0600423,C4055506,TREATS,Benzoic Acids,Accumulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0600437,C4086268,TREATS,Nitric Oxide Donors,Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0602392,C0150312,TREATS,T-18,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0615769,C0683321,TREATS,feral,Poor Health,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0635657,C4288557,TREATS,"N-(2,6-dimethylphenyl)-4-(((diethylamino)acetyl)amino)benzamide",One Activity Hour,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0641352,C0150312,TREATS,trans-dihydronarciclasine,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0677942,C1513183,TREATS,samarium Sm153,Metastatic Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0678485,C3714738,TREATS,controlled substance,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0683092,C4699604,TREATS,intravenous drug,<12 months,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0718215,C0017187,TREATS,ACIDOPHILUS,Gastrointestinal problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0718215,C0686744,TREATS,ACIDOPHILUS,Well child,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0719214,C0595998,TREATS,Century (brand of multivitamin),Household composition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0719214,C1516998,TREATS,Century (brand of multivitamin),Exogenous Factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0719214,C1659989,TREATS,Century (brand of multivitamin),Respiratory problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0722884,C0429706,TREATS,Provocholine,Forced expiratory volume in 1 second finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0749139,C0085393,TREATS,sulfa,Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0751968,C0422837,TREATS,Enzyme Activators,Neurological observations,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0770667,C0332155,TREATS,Nifuraldezone,Did not receive therapy or drug for,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0770751,C0150312,TREATS,ANTISEPTIC SOLUTION,Present,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0872285,C0150312,TREATS,therapeutic protein,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0872285,C1836348,TREATS,therapeutic protein,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0875962,C0033213,TREATS,Anti-Gas,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0907767,C0221198,TREATS,"N(6)-cyclopropyl-9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine",Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0914297,C0679246,TREATS,oblimersen,advanced disease,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0935929,C0428886,TREATS,Antidiabetics,Mean blood pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C0035648,TREATS,lopinavir / Ritonavir,risk factors,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C0151878,TREATS,lopinavir / Ritonavir,Prolonged QT interval,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0939237,C0332149,TREATS,lopinavir / Ritonavir,Possible,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C0425946,TREATS,lopinavir / Ritonavir,Short menstrual periods,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C0439663,TREATS,lopinavir / Ritonavir,Infected,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C0518609,TREATS,lopinavir / Ritonavir,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C0679250,TREATS,lopinavir / Ritonavir,Disease Outcome,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C0701159,TREATS,lopinavir / Ritonavir,Patient in hospital,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0939237,C1290916,TREATS,lopinavir / Ritonavir,Radiologic finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C1317600,TREATS,lopinavir / Ritonavir,patient symptoms,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C1836348,TREATS,lopinavir / Ritonavir,Severe disorder,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C0939237,C1848676,TREATS,lopinavir / Ritonavir,Normal liver function,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C0939237,C2004062,TREATS,lopinavir / Ritonavir,History of previous events,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C2029943,TREATS,lopinavir / Ritonavir,Transplanted heart present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C3272281,TREATS,lopinavir / Ritonavir,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C3272903,TREATS,lopinavir / Ritonavir,Overall Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C3811922,TREATS,lopinavir / Ritonavir,Liver transplant recipient,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C4050466,TREATS,lopinavir / Ritonavir,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939237,C4698719,TREATS,lopinavir / Ritonavir,Confirmed case,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939806,C0262477,TREATS,Matricaria recutita extract,Eye problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0939831,C0241863,TREATS,Beta vulgaris homeopathic preparation,diabetic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C0949573,C0439663,TREATS,HIV Fusion Inhibitors,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0949854,C0436343,TREATS,Plant Preparations,Symptom mild,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0949854,C0439663,TREATS,Plant Preparations,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0949854,C1262477,TREATS,Plant Preparations,Weight decreased,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0961026,C0439663,TREATS,"(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate",Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0968269,C0221198,TREATS,luteoforol,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C0972343,C0150312,TREATS,veratraldehyde,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1101504,C0150312,TREATS,azidotrimethylsilane,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136250,C1273489,TREATS,Controlled-Release Preparations,Asthma night-time symptoms,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0033213,TREATS,Microbicides,Problem,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1136254,C0035648,TREATS,Microbicides,risk factors,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1136254,C0043084,TREATS,Microbicides,Weaning,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0150312,TREATS,Microbicides,Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1136254,C0221198,TREATS,Microbicides,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0235896,TREATS,Microbicides,Pulmonary Infiltrate,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0240807,TREATS,Microbicides,PROGRESSIVE SYMPTOMS,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0277803,TREATS,Microbicides,Normal vital signs,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0332155,TREATS,Microbicides,Did not receive therapy or drug for,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0332219,TREATS,Microbicides,Easy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0424768,TREATS,Microbicides,Prolonged fever,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0425946,TREATS,Microbicides,Short menstrual periods,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0439663,TREATS,Microbicides,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0520819,TREATS,Microbicides,Decreased pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0576962,TREATS,Microbicides,Tooth problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0743630,TREATS,Microbicides,exacerbation acute,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C1136254,C0749647,TREATS,Microbicides,treatment empiric,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0750479,TREATS,Microbicides,blank,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C0750558,TREATS,Microbicides,Unlikely,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1136254,C1277248,TREATS,Microbicides,General health poor,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C1318963,TREATS,Microbicides,Readiness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C1545588,TREATS,Microbicides,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C1709157,TREATS,Microbicides,Negative Surgical Margin,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C1859430,TREATS,Microbicides,Life-threatening infections,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C2364300,TREATS,Microbicides,Actual Adequate Hydration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C3272281,TREATS,Microbicides,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1136254,C3272283,TREATS,Microbicides,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136254,C4086268,TREATS,Microbicides,Exacerbation,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C1136254,C4264624,TREATS,Microbicides,Likely pathogenic,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1136254,C4321351,TREATS,Microbicides,Low Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1136312,C0349790,TREATS,"Histamine H1 Antagonists, Non-Sedating",Exacerbation of asthma,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1258800,C2598387,TREATS,Anabolic Agents,Overall status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1268551,C3272283,TREATS,Echinocandins,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1268865,C0442797,TREATS,Prokinetic Agent,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1268865,C1820738,TREATS,Prokinetic Agent,Feeding intolerance,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1268919,C0085393,TREATS,Fungal product,Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1275666,C0150312,TREATS,Substance with Human immunodeficiency virus fusion inhibitor mechanism of action (substance),Present,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1276807,C0429706,TREATS,Budesonide / formoterol,Forced expiratory volume in 1 second finding,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1299007,C3843708,TREATS,alpha-Glucosidase Inhibitors,29+,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1306772,C4086268,TREATS,tiotropium bromide,Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1330330,C3714738,TREATS,Hand Sanitizers,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1337242,C1444662,TREATS,cinacalcet,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1360419,C4068826,TREATS,Herbal Drugs,Harsh,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1433854,C0150312,TREATS,squaraine,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1443643,C0033213,TREATS,Proteasome inhibitor,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1443650,C0009488,TREATS,Neuraminidase inhibitor,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1443650,C0085393,TREATS,Neuraminidase inhibitor,Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1443650,C0332149,TREATS,Neuraminidase inhibitor,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1443650,C5203671,TREATS,Neuraminidase inhibitor,Suspected COVID-19,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1449680,C0241863,TREATS,Angiotensin II Type 1 Receptor Blockers,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1513016,C0439663,TREATS,Matrix Metalloproteinase Inhibitors,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1514669,C0686750,TREATS,RNA Polymerase Inhibitor,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1514727,C0150312,TREATS,Ras Inhibitor,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1514727,C0241863,TREATS,Ras Inhibitor,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1514727,C3272283,TREATS,Ras Inhibitor,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1516250,C0429753,TREATS,Carbohydrate Processing Inhibitor,Alveolar volume,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1516312,C4321237,TREATS,Caspase Inhibitors,High Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1520007,C0033213,TREATS,Viral Vector,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1520007,C0232370,TREATS,Viral Vector,Florid red complexion (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1520007,C0238646,TREATS,Viral Vector,ANIMAL EXPOSURE,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1520007,C1299586,TREATS,Viral Vector,Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1520007,C4321237,TREATS,Viral Vector,High Level,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1529314,C4321351,TREATS,Baycox,Low Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1563745,C3272283,TREATS,Selective Angiotensin II Receptor Antagonists,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1565493,C0038435,TREATS,sinapyl alcohol,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1579268,C1299586,TREATS,Mineralocorticoid Receptor Antagonists,Has difficulty doing (qualifier value),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1579422,C0750484,TREATS,Anti-influenza Agents,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1695579,C0419437,TREATS,alglucosidase alfa,High risk infant,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1704311,C3251812,TREATS,Antithrombotic Agents,Bleeding risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1704311,C3272283,TREATS,Antithrombotic Agents,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1709545,C3272283,TREATS,Piperine Extract (Standardized),American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1718097,C0009488,TREATS,New medications,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1718097,C0038435,TREATS,New medications,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1718097,C0333361,TREATS,New medications,Acute inflammation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1718097,C0686750,TREATS,New medications,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1718097,C0746467,TREATS,New medications,Current Medication,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1827106,C0241863,TREATS,Dipeptidyl-Peptidase IV Inhibitors,diabetic,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C1827106,C3272281,TREATS,Dipeptidyl-Peptidase IV Inhibitors,American College of Cardiology/American Heart Association Lesion Complexity Score A,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1827106,C4699158,TREATS,Dipeptidyl-Peptidase IV Inhibitors,Increased risk,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874271,C0221198,TREATS,"ANTIBACTERIAL,TOPICAL",Lesion,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874300,C4554631,TREATS,"ANTIHISTAMINES,NASAL","Nasal Congestion, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874321,C0150312,TREATS,ANTISEPTICS/DISINFECTANTS,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0003126,TREATS,Basis,Anosmia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0009488,TREATS,Basis,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0015663,TREATS,Basis,Fasting,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0020461,TREATS,Basis,Hyperkalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0020621,TREATS,Basis,Hypokalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0026751,TREATS,Basis,Multiparity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0027854,TREATS,Basis,Neurologic Manifestations,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0033213,TREATS,Basis,Problem,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1874451,C0035648,TREATS,Basis,risk factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0037420,TREATS,Basis,Social Interaction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0038435,TREATS,Basis,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0085393,TREATS,Basis,Immunocompromised Host,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0087130,TREATS,Basis,Uncertainty,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0150312,TREATS,Basis,Present,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C1874451,C0184511,TREATS,Basis,Improved,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1874451,C0205557,TREATS,Basis,False Positive,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0221198,TREATS,Basis,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0231171,TREATS,Basis,Physical impairment,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0231221,TREATS,Basis,Asymptomatic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0231224,TREATS,Basis,Crisis,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0231303,TREATS,Basis,Distress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0232370,TREATS,Basis,Florid red complexion (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0237849,TREATS,Basis,Peeling of skin,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0239846,TREATS,Basis,Hand-wringing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0240320,TREATS,Basis,medication use,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0241526,TREATS,Basis,Unresponsiveness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0241863,TREATS,Basis,diabetic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0277787,TREATS,Basis,Social stigmata,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0332148,TREATS,Basis,Probable diagnosis,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0332149,TREATS,Basis,Possible,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1874451,C0332509,TREATS,Basis,Increased size (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0337664,TREATS,Basis,Smoker,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0340871,TREATS,Basis,Relative hypovolemia,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0344339,TREATS,Basis,Family illness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0376705,TREATS,Basis,Viral Load result,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0392209,TREATS,Basis,Nutritional status,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0425152,TREATS,Basis,Engaged to be married,phsu,fndg,8,TREATS_PHSUtrtsFNDG
C1874451,C0425382,TREATS,Basis,Personal status - Adopted,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0427184,TREATS,Basis,No incoordination,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0439663,TREATS,Basis,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0442726,TREATS,Basis,Detected (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0518609,TREATS,Basis,Consideration,phsu,fndg,6,TREATS_PHSUtrtsFNDG
C1874451,C0520966,TREATS,Basis,Abnormal coordination,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0521654,TREATS,Basis,Neurologic Deficits,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0521874,TREATS,Basis,Victim of neglect (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0574125,TREATS,Basis,Functional finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0595998,TREATS,Basis,Household composition,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0600457,TREATS,Basis,Gravidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0679246,TREATS,Basis,advanced disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0679250,TREATS,Basis,Disease Outcome,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C0743630,TREATS,Basis,exacerbation acute,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C0750484,TREATS,Basis,Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1148454,TREATS,Basis,seizure activity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1260922,TREATS,Basis,Abnormal breathing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1279682,TREATS,Basis,Clever,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1281905,TREATS,Basis,At risk of disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1290905,TREATS,Basis,Discrepancy (finding),phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C1290916,TREATS,Basis,Radiologic finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1299487,TREATS,Basis,Patient name,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1318963,TREATS,Basis,Readiness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1446614,TREATS,Basis,Convergent gaze,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1545588,TREATS,Basis,Protection,phsu,fndg,7,TREATS_PHSUtrtsFNDG
C1874451,C1709157,TREATS,Basis,Negative Surgical Margin,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1832073,TREATS,Basis,Handling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1836348,TREATS,Basis,Severe disorder,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C1837385,TREATS,Basis,Poor growth,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1837514,TREATS,Basis,Phenotypic Variation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1844666,TREATS,Basis,Immune dysregulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1846356,TREATS,Basis,Clinical variation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1879646,TREATS,Basis,Affected Area,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C1998720,TREATS,Basis,Effective Communication,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C2004062,TREATS,Basis,History of previous events,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C2984802,TREATS,Basis,Interoperability Problem Identified,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3242274,TREATS,Basis,new therapy,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3258145,TREATS,Basis,Secondary problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3272283,TREATS,Basis,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C3273245,TREATS,Basis,Acute Rejection,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C3280470,TREATS,Basis,Benign condition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3494749,TREATS,Basis,Animal - origin,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3714738,TREATS,Basis,Compliance,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3827002,TREATS,Basis,Ground Glass Opacity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C3841253,TREATS,Basis,Reusable,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C4018909,TREATS,Basis,Overdose,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C4050466,TREATS,Basis,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1874451,C4055506,TREATS,Basis,Accumulation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C4698386,TREATS,Basis,Intubated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C4699158,TREATS,Basis,Increased risk,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1874451,C4699181,TREATS,Basis,Lattice,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1874451,C5194866,TREATS,Basis,Increased infections,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1875235,C0740852,TREATS,Helium / Oxygen,Upper airway obstruction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1875384,C0562577,TREATS,INVESTIGATIONAL VACCINES,Mocking,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1875784,C0023974,TREATS,STEP 2,Loneliness,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C1875784,C1854293,TREATS,STEP 2,Iterations,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C1883555,C0443213,TREATS,Whey Protein Isolate,Extrusion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C1998014,C3280118,TREATS,Denufosol,Mild disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2241979,C0085393,TREATS,Salmonella typhi Ty21a live antigen,Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2266974,C0085393,TREATS,Echinocandin Antifungal [EPC],Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2343929,C0221198,TREATS,Tumor Necrosis Factor Blocker [EPC],Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2347168,C0033213,TREATS,Mitogen-Activated Protein Kinase Kinase Inhibitor,Problem,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C2347168,C0150312,TREATS,Mitogen-Activated Protein Kinase Kinase Inhibitor,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2348075,C3890735,TREATS,darapladib,Complete Response with Incomplete Platelet Recovery,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2698842,C0043094,TREATS,hiltonol,Weight Gain,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2719416,C0150312,TREATS,Vortex,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2743950,C0231224,TREATS,Oxyglobin,Crisis,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2746051,C0600457,TREATS,DNA Polymerase Inhibitors,Gravidity,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C2746052,C1444662,TREATS,mTOR Inhibitor,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2917414,C0150312,TREATS,Recombinant Human Deoxyribonuclease 1 [EPC],Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2917446,C0232341,TREATS,Vasopressin Analog,Increased vascular flow,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2927794,C0750484,TREATS,RFD,Confirmation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C2927794,C5203671,TREATS,RFD,Suspected COVID-19,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C2936609,C0337671,TREATS,Phosphodiesterase 4 Inhibitors,Former smoker,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2947577,C0022107,TREATS,Dioscorea villosa tuber extract,Irritable Mood,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2954564,C0150312,TREATS,Suppressor,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2954564,C1864829,TREATS,Suppressor,Praxis,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C2954564,C4321237,TREATS,Suppressor,High Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3166216,C0241863,TREATS,Prescribed medications,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3191774,C1545588,TREATS,Methanol Solution,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3205666,C0029162,TREATS,Oral Product,Oral health,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3241999,C0035648,TREATS,limited use,risk factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3241999,C0598463,TREATS,limited use,Functional Status,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3272847,C0728725,TREATS,Losmapimod,Low pH,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3273153,C0150312,TREATS,Drug Sample,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3273711,C3272283,TREATS,ixazomib,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3467777,C1545588,TREATS,Ag 3340,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3485977,C0231221,TREATS,Autologous Cellular Immunotherapy,Asymptomatic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3490795,C0429673,TREATS,asfotase alfa,Respiratory measure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537002,C0429306,TREATS,Anti-epileptic Agent [EPC],Burst suppression,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537128,C1845208,TREATS,Vasopressin Antagonist,Euvolemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537161,C0001925,TREATS,Dipeptidyl Peptidase 4 Inhibitor [EPC],Albuminuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537192,C0439663,TREATS,Tumor Necrosis Factor Inhibitors,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537192,C3840775,TREATS,Tumor Necrosis Factor Inhibitors,Anticipated,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3537218,C0085393,TREATS,Neuraminidase Inhibitor [EPC],Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537218,C0750484,TREATS,Neuraminidase Inhibitor [EPC],Confirmation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537218,C1836348,TREATS,Neuraminidase Inhibitor [EPC],Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3537226,C0038435,TREATS,Adenosine Receptor Agonist,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0009488,TREATS,other medicated shampoos in ATC,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0012154,TREATS,other medicated shampoos in ATC,Diestrus,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0015663,TREATS,other medicated shampoos in ATC,Fasting,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0020440,TREATS,other medicated shampoos in ATC,Hypercapnia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0021294,TREATS,other medicated shampoos in ATC,"Infant, Premature",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0033213,TREATS,other medicated shampoos in ATC,Problem,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C3539125,C0035648,TREATS,other medicated shampoos in ATC,risk factors,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0037420,TREATS,other medicated shampoos in ATC,Social Interaction,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C3539125,C0038435,TREATS,other medicated shampoos in ATC,Stress,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0087130,TREATS,other medicated shampoos in ATC,Uncertainty,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0150312,TREATS,other medicated shampoos in ATC,Present,phsu,fndg,8,TREATS_PHSUtrtsFNDG
C3539125,C0221198,TREATS,other medicated shampoos in ATC,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0231221,TREATS,other medicated shampoos in ATC,Asymptomatic,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0231224,TREATS,other medicated shampoos in ATC,Crisis,phsu,fndg,7,TREATS_PHSUtrtsFNDG
C3539125,C0231303,TREATS,other medicated shampoos in ATC,Distress,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C3539125,C0240322,TREATS,other medicated shampoos in ATC,Menstrual period late,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0241863,TREATS,other medicated shampoos in ATC,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0262926,TREATS,other medicated shampoos in ATC,Medical History,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0332149,TREATS,other medicated shampoos in ATC,Possible,phsu,fndg,3,TREATS_PHSUtrtsFNDG
C3539125,C0332575,TREATS,other medicated shampoos in ATC,Redness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0349790,TREATS,other medicated shampoos in ATC,Exacerbation of asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0424000,TREATS,other medicated shampoos in ATC,Feeling suicidal (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0424403,TREATS,other medicated shampoos in ATC,Erotic feeling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0425152,TREATS,other medicated shampoos in ATC,Engaged to be married,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0427184,TREATS,other medicated shampoos in ATC,No incoordination,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0428642,TREATS,other medicated shampoos in ATC,Pulmonary artery pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0436343,TREATS,other medicated shampoos in ATC,Symptom mild,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0439663,TREATS,other medicated shampoos in ATC,Infected,phsu,fndg,4,TREATS_PHSUtrtsFNDG
C3539125,C0476644,TREATS,other medicated shampoos in ATC,Physical and emotional exhaustion state,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0489618,TREATS,other medicated shampoos in ATC,pupil diameter,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0518609,TREATS,other medicated shampoos in ATC,Consideration,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0549336,TREATS,other medicated shampoos in ATC,asthma aggravated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0557074,TREATS,other medicated shampoos in ATC,Second language,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0577305,TREATS,other medicated shampoos in ATC,Multiple lesions,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0578862,TREATS,other medicated shampoos in ATC,Intraocular pressure finding,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0595998,TREATS,other medicated shampoos in ATC,Household composition,phsu,fndg,5,TREATS_PHSUtrtsFNDG
C3539125,C0600457,TREATS,other medicated shampoos in ATC,Gravidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0680074,TREATS,other medicated shampoos in ATC,family role (history),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0681405,TREATS,other medicated shampoos in ATC,Preschool Completion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0683314,TREATS,other medicated shampoos in ATC,personal health,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0686744,TREATS,other medicated shampoos in ATC,Well child,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0750479,TREATS,other medicated shampoos in ATC,blank,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0750484,TREATS,other medicated shampoos in ATC,Confirmation,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C0814098,TREATS,other medicated shampoos in ATC,health-related beliefs,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C0848894,TREATS,other medicated shampoos in ATC,normal patient,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1281905,TREATS,other medicated shampoos in ATC,At risk of disease,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1320226,TREATS,other medicated shampoos in ATC,Incubation period,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1446377,TREATS,other medicated shampoos in ATC,Mental health problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1446614,TREATS,other medicated shampoos in ATC,Convergent gaze,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C1519789,TREATS,other medicated shampoos in ATC,Unexpected Adverse Event,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1545588,TREATS,other medicated shampoos in ATC,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1547326,TREATS,other medicated shampoos in ATC,Unconfirmed,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1832073,TREATS,other medicated shampoos in ATC,Handling,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1836348,TREATS,other medicated shampoos in ATC,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C1844666,TREATS,other medicated shampoos in ATC,Immune dysregulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C3272283,TREATS,other medicated shampoos in ATC,American College of Cardiology/American Heart Association Lesion Complexity Score C,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C3280118,TREATS,other medicated shampoos in ATC,Mild disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C3687379,TREATS,other medicated shampoos in ATC,Lateral recumbency,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C3840880,TREATS,other medicated shampoos in ATC,Traffic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C3842677,TREATS,other medicated shampoos in ATC,Very hard,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4050466,TREATS,other medicated shampoos in ATC,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4055506,TREATS,other medicated shampoos in ATC,Accumulation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4068826,TREATS,other medicated shampoos in ATC,Harsh,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C4289767,TREATS,other medicated shampoos in ATC,Colonization,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3539125,C4321237,TREATS,other medicated shampoos in ATC,High Level,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4534363,TREATS,other medicated shampoos in ATC,At home,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4697706,TREATS,other medicated shampoos in ATC,Macrocephalic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C4745084,TREATS,other medicated shampoos in ATC,Medical Condition,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C5141930,TREATS,other medicated shampoos in ATC,Casualties,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539125,C5204818,TREATS,other medicated shampoos in ATC,Global Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0033213,TREATS,opium alkaloids and derivative combination cough suppressants,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0038435,TREATS,opium alkaloids and derivative combination cough suppressants,Stress,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0150312,TREATS,opium alkaloids and derivative combination cough suppressants,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0235874,TREATS,opium alkaloids and derivative combination cough suppressants,Disease Exacerbation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0332149,TREATS,opium alkaloids and derivative combination cough suppressants,Possible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C0332575,TREATS,opium alkaloids and derivative combination cough suppressants,Redness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C1545588,TREATS,opium alkaloids and derivative combination cough suppressants,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C1854293,TREATS,opium alkaloids and derivative combination cough suppressants,Iterations,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3539957,C4698019,TREATS,opium alkaloids and derivative combination cough suppressants,Incompatible,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3541969,C0085393,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Immunocompromised Host,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3541969,C0087130,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Uncertainty,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3541969,C0686750,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3541969,C1318963,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Readiness,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3541969,C1545588,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3541969,C1836348,TREATS,"Neuraminidase inhibitors, direct acting antivirals",Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3543842,C0015663,TREATS,TONICS,Fasting,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3543842,C0231162,TREATS,TONICS,Normal general body function,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3543842,C0241863,TREATS,TONICS,diabetic,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3543842,C0424589,TREATS,TONICS,Vitality,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3543842,C1272641,TREATS,TONICS,Systemic arterial pressure,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3543842,C1631070,TREATS,TONICS,6/4.5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3556178,C1444656,TREATS,Tecfidera,Indicated,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3642466,C0560435,TREATS,Savolitinib,Does skip,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3651790,C1881707,TREATS,egg shell membrane,Material Degradation,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3653501,C0439663,TREATS,DIRECT ACTING ANTIVIRALS,Infected,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3653501,C4050171,TREATS,DIRECT ACTING ANTIVIRALS,Sustained Virologic Response,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3653788,C0020461,TREATS,ANTIANEMIC PREPARATIONS,Hyperkalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3653788,C3665437,TREATS,ANTIANEMIC PREPARATIONS,Serum phosphate concentrations above normal (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3654000,C0422837,TREATS,SENSORY ORGAN DRUGS,Neurological observations,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3656593,C0686750,TREATS,ceftolozane / tazobactam,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3659863,C0686750,TREATS,V710 vaccine,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3661039,C1545588,TREATS,WDO-217,Protection,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3819026,C4014463,TREATS,Interleukin-6 Receptor Antagonist [EPC],Hyperinflammatory state,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3819026,C4050466,TREATS,Interleukin-6 Receptor Antagonist [EPC],Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3824716,C0349790,TREATS,Ketolide antibiotics,Exacerbation of asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3827187,C3476649,TREATS,Instanyl,Treatment satisfaction,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3838940,C1838994,TREATS,Stonefish antivenom,Rapid onset,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3853872,C0150312,TREATS,electrolyte solution,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3853872,C3280502,TREATS,electrolyte solution,"Diarrhea, malabsorptive",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3854325,C1836348,TREATS,Janus kinase inhibitor,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3854325,C1850165,TREATS,Janus kinase inhibitor,Elevated IL6,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3854325,C4321237,TREATS,Janus kinase inhibitor,High Level,phsu,fndg,2,TREATS_PHSUtrtsFNDG
C3858051,C1148363,TREATS,ledipasvir / sofosbuvir,Hepatitis C virus genotype (finding),phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3864917,C4050466,TREATS,Interleukin-6 Antagonist,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3883356,C0020649,TREATS,Lipid Emulsion,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3883357,C0150312,TREATS,Hepatitis C Virus NS5A Inhibitor,Present,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C3897599,C0033213,TREATS,Skin Care Product,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4018264,C0033213,TREATS,stearamide,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4045522,C0020461,TREATS,patiromer,Hyperkalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4267721,C0021294,TREATS,Surfactant replacement,"Infant, Premature",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4305789,C3670803,TREATS,delta1-Dihydrotestosterone,Cartilage lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4305867,C4531251,TREATS,Sirna-027,Subfoveal choroidal neovascularization,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4330505,C0038002,TREATS,JAK1 Inhibitor,Splenomegaly,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4330505,C1843376,TREATS,JAK1 Inhibitor,"Pulmonary involvement, severe",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4330852,C0221198,TREATS,Oligomeric Procyanidin Complex,Lesion,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4330852,C2752010,TREATS,Oligomeric Procyanidin Complex,Decreased myelin,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4331423,C0436343,TREATS,Traditional Chinese Medicine Formulation,Symptom mild,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4490035,C4050466,TREATS,infliximab-abda,Borg Category-Ratio 10 Perceived Exertion Score 5,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4505530,C0349790,TREATS,nemolizumab,Exacerbation of asthma,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4521445,C5141930,TREATS,Plasma Product,Casualties,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4524580,C0332797,TREATS,Single Donor Plasma,wounded,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4524590,C1560209,TREATS,Washed Red Blood Cells,"Hemolysis, CTCAE",phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4694977,C0020461,TREATS,Lokelma,Hyperkalemia,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4704928,C0686750,TREATS,Antibody-Drug Conjugates,Well adult,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4745142,C0033213,TREATS,HSP90 Inhibitor,Problem,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C4761425,C0442797,TREATS,HIV Entry Inhibitor,Decreasing,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5139926,C0085393,TREATS,DAS-181,Immunocompromised Host,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5139963,C0376705,TREATS,MHAA4549A,Viral Load result,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5147552,C0020649,TREATS,Inotropic support,Hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5147552,C4304283,TREATS,Inotropic support,Refractory hypotension,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5214487,C0009488,TREATS,Antiplatelet,Comorbidity,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5214487,C0035648,TREATS,Antiplatelet,risk factors,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5214487,C1444662,TREATS,Antiplatelet,Discontinued,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5214487,C1836348,TREATS,Antiplatelet,Severe disorder,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5214487,C4697669,TREATS,Antiplatelet,Reconstituted,phsu,fndg,1,TREATS_PHSUtrtsFNDG
C5227675,C4546070,TREATS,TTP488,Persistent albuminuria,phsu,fndg,1,TREATS_PHSUtrtsFNDG
